title: The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.
abstract: OBJECTIVE
  This study was performed to investigate the impact of HAART versus no HAART and nucleoside free versus nucleoside containing HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV/HCV co-infected patients. In addition a control group of HCV mono-infected patients undergoing anti-HCV therapy was evaluated.
  
  
  METHODS
  Multicenter, partially randomized, controlled clinical trial. HIV-negative and -positive patients with chronic HCV infection were treated with pegylated interferon alfa-2a and ribavirin (800 - 1200 mg/day) for 24 - 48 weeks in one of four treatment arms: HIV-negative (A), HIV-positive without HAART (B) and HIV-positive on HAART (C). Patients within arm C were randomized to receive open label either a nucleoside containing (C1) or a nucleoside free HAART (C2).
  
  
  RESULTS
  168 patients were available for analysis. By intent-to-treat analysis similar sustained virological response rates (SVR, negative HCV-RNA 24 weeks after the end of therapy) were observed comparing HIV-negative and -positive patients (54% vs. 54%, p = 1.000). Among HIV-positive patients SVR rates were similar between patients off and on HAART (57% vs. 52%, p = 0.708). Higher SVR rates were observed in patients on a nucleoside free HAART compared to patients on a nucleoside containing HAART, though confounding could not be ruled out and in the intent-to-treat analysis the difference was not statistically significant (64% vs. 46%, p = 0.209).
  
  
  CONCLUSIONS
  Similar response rates for HCV therapy can be achieved in HIV-positive and -negative patients. Patients on nucleoside free HAART reached at least equal rates of sustained virological response compared to patients on standard HAART.
authors.affiliation: Department of Internal Medicine I, Rheinische friedrich-Wilhelms-University, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Vogel
authors.forename: G
authors.initials: G
authors.lastname: Ahlenstiel
authors.forename: B
authors.initials: B
authors.lastname: Hintsche
authors.forename: S
authors.initials: S
authors.lastname: Fenske
authors.forename: A
authors.initials: A
authors.lastname: Trein
authors.forename: T
authors.initials: T
authors.lastname: Lutz
authors.forename: D
authors.initials: D
authors.lastname: Schürmann
authors.forename: C
authors.initials: C
authors.lastname: Stephan
authors.forename: P
authors.initials: P
authors.lastname: Khaykin
authors.forename: M
authors.initials: M
authors.lastname: Bickel
authors.forename: C
authors.initials: C
authors.lastname: Mayr
authors.forename: A
authors.initials: A
authors.lastname: Baumgarten
authors.forename: P
authors.initials: P
authors.lastname: Buggisch
authors.forename: H
authors.initials: H
authors.lastname: Klinker
authors.forename: C
authors.initials: C
authors.lastname: John
authors.forename: J
authors.initials: J
authors.lastname: Gölz
authors.forename: S
authors.initials: S
authors.lastname: Staszewski
authors.forename: J K
authors.initials: JK
authors.lastname: Rockstroh
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D004337:Drug Carriers; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D016174:Hepacivirus / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
references.citation: J Viral Hepat. 2008 Apr;15(4):255-60
references.pmid: 18307589
references.citation: N Engl J Med. 2004 Jul 29;351(5):451-9
references.pmid: 15282352
references.citation: JAMA. 2004 Dec 15;292(23):2839-48
references.pmid: 15598915
references.citation: Clin Infect Dis. 2009 Oct 15;49(8):e84-91
references.pmid: 19772388
references.citation: Antivir Ther. 2008;13(7):953-7
references.pmid: 19043930
references.citation: J Viral Hepat. 2007 Sep;14(9):639-44
references.pmid: 17697016
references.citation: Antivir Ther. 2008;13(3):429-37
references.pmid: 18572756
references.citation: J Antimicrob Chemother. 2008 Dec;62(6):1365-73
references.pmid: 18854330
references.citation: J Antimicrob Chemother. 2007 Dec;60(6):1347-54
references.pmid: 17938129
references.citation: J Viral Hepat. 2007 Mar;14(3):183-8
references.pmid: 17305884
references.citation: Antivir Ther. 2007;12(8):1225-35
references.pmid: 18240862
references.citation: J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52
references.pmid: 16123681
references.citation: J Antimicrob Chemother. 2009 Jun;63(6):1256-63
references.pmid: 19363085
references.citation: J Infect Dis. 2008 Nov 1;198(9):1337-44
references.pmid: 18767985
references.citation: J Acquir Immune Defic Syndr. 2007 May 1;45(1):123-5
references.pmid: 17460476
references.citation: N Engl J Med. 2004 Jul 29;351(5):438-50
references.pmid: 15282351
references.citation: J Viral Hepat. 2008 May;15(5):363-9
references.pmid: 18179454
references.citation: Hepatology. 2009 Aug;50(2):407-13
references.pmid: 19575364
references.citation: Antivir Ther. 2005;10(3):423-9
references.pmid: 15918333
references.citation: Ann Intern Med. 2004 Mar 2;140(5):346-55
references.pmid: 14996676
references.citation: AIDS. 2004 Sep 3;18(13):F27-36
references.pmid: 15316335
references.citation: J Viral Hepat. 2006 Oct;13(10):683-9
references.pmid: 16970600
references.citation: Hepatology. 2009 Jan;49(1):22-31
references.pmid: 19085908
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: J Infect. 2006 Jul;53(1):36-42
references.pmid: 16269184
references.citation: AIDS Res Hum Retroviruses. 2007 Aug;23(8):972-82
references.pmid: 17725413
references.citation: J Infect Dis. 2005 Sep 15;192(6):992-1002
references.pmid: 16107951
references.citation: J Hepatol. 2005 May;42(5):615-24
references.pmid: 15916745
references.citation: Clin Infect Dis. 2004 Jan 1;38(1):128-33
references.pmid: 14679458